Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-03.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 88 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 89 Clinical Implications of Glucose Variability: Chronic Complications of Diabetes
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Endocrinol Metab > Volume 30(2); 2015 > Article
Review Article
Clinical Implications of Glucose Variability: Chronic Complications of Diabetes
Hye Seung Jung
Endocrinology and Metabolism 2015;30(2):167-174.
DOI: https://doi.org/10.3803/EnM.2015.30.2.167
Published online: June 30, 2015

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Corresponding author: Hye Seung Jung. Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea. Tel: +82-2-2072-0240, Fax: +82-2-762-9662, junghs@snu.ac.kr
• Received: May 19, 2015   • Revised: May 22, 2015   • Accepted: May 22, 2015

Copyright © 2015 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 5,579 Views
  • 93 Download
  • 66 Web of Science
  • 68 Crossref
  • 75 Scopus
  • Glucose variability has been identified as a potential risk factor for diabetic complications; oxidative stress is widely regarded as the mechanism by which glycemic variability induces diabetic complications. However, there remains no generally accepted gold standard for assessing glucose variability. Representative indices for measuring intraday variability include calculation of the standard deviation along with the mean amplitude of glycemic excursions (MAGE). MAGE is used to measure major intraday excursions and is easily measured using continuous glucose monitoring systems. Despite a lack of randomized controlled trials, recent clinical data suggest that long-term glycemic variability, as determined by variability in hemoglobin A1c, may contribute to the development of microvascular complications. Intraday glycemic variability is also suggested to accelerate coronary artery disease in high-risk patients.
Diabetic patients with similar mean glucose levels often exhibit differences in terms of both the number and degree of glucose excursions. This phenomenon, termed glucose variability, has been suggested as a factor associated with diabetic complications. The development of continuous glucose monitoring (CGM) systems has revolutionized the monitoring of short-term glucose variability, and understanding of the role of glucose fluctuations is in progress. Here, we provide an overview of the methods used to measure glucose variability and review the literatures on clinical implications associated with glucose variability.
Table 1 describes the formulas underlying commonly used measurements and their characteristics. There is no generally accepted gold standard and little consensus regarding which method offers the most meaningful assessment of glucose variability. Among the most commonly used methods is the standard deviation (SD). It can be calculated from self-monitoring of blood glucose (SMBG) levels. Since CGM was available, the mean amplitude of glycemic excursions (MAGE) has been widely used, too.
To avoid distortions in variability due to glycemic exposure, calculations of glucose variability should be devoid of a time component: glucose excursion×time=glycemic exposure, but not variability. Similarly, the formula glucose excursion/time=slope is the rate of glucose change, but not its magnitude [1]. Unlike the integrated measurement of long-term glucose control provided by hemoglobin A1c (HbA1c), glycemic variability requires comprehensive assessment of glycemia. CGM systems provide a more accurate measure of glycemia than does SMBG; however, issues of reproducibility limit the utility of this approach [2].
Intraday variability
The simplest method of assessing intra-day variability of serum glucose is to calculate the SD or coefficient of variation (CV) of multiple SMBG readings taken over the course of a day. Usually 7-point glucose measures are used, although important fluctuations can be missed simply because they occur between two measurements (Fig. 1). Furthermore, it is difficult to obtain information on nocturnal glycemic patterns. CGM systems are able to overcome many of the issues with SMBG glucose curves, though the data are still not normally distributed, a condition necessary for calculating the SD. However, the SD correlates well with other variability measures and is the only measurement identified to date where a relationship between glucose variability and mortality in intensive care unit can be demonstrated [34]. For these reasons, some groups have suggested the SD as the preferred method for assessing intraday glucose variability [5].
MAGE was originally developed using hourly glucose samples taken from venous blood [6], and it has emerged as the preferred method for assessing CGM data. In the example presented in Fig. 2, 1 SD of the mean glucose level for each 24-hour period acts as an individualized standard; only one limb of the excursion >1 SD, either ascending or descending, is used to calculate subsequent excursions. The arithmetic mean of these glycemic excursions over the period of study (24 hours or longer) is then used to calculate the MAGE; an automated algorithm has been created for this calculation [7]. Using this method, the mean glucose value becomes the reference point for glycemic variability. However, because the MAGE represents only major excursions from the mean and ignores excursions of <1 SD, this approach disregards smaller excursions that may be important.
The M-value was developed to quantify glycemic control of patients with type 1 diabetes mellitus (T1DM) using a reference value of six blood sugar measurements taken over a 24-hour period [8]. This approach measures the stability of glucose excursions relative to a user-defined "ideal" value ranging from 80 to 120 mg/dL. As a result, differences in user-defined "ideal" values have limited the ability to compare results between studies. In addition, M-values rise in response to increasing glycemic variability and poor glycemic control, making it difficult to distinguish between patients with high mean glucose levels and high glucose variability. Because hypoglycemia has a greater impact on the M-value than does hyperglycemia, this method is more relevant as a clinical, rather than a mathematical, indicator of glycemic control. A similar index which takes into account both the mean glucose level and variability of glycemia is the J-index [9].
In 1999, a new method, continuous overall net glycemic action (CONGA)-n, was developed specifically for use with CGM data [10]. This method calculates the difference between current glucose levels and that of glucose levels n hours previously, with n varying from 1 to 8 hours; readouts are then calculated using the SD of these differences. Because CONGA does not require arbitrarily defined glucose cutoffs or changes in glucose levels, this approach provides an objective assessment of glycemic variability over short time intervals. However, glucose differences are not normally distributed, limiting the applicability of this approach. Furthermore, which time segments produce the most useful results has yet to be determined.
Outside of measuring glucose itself, serum 1,5-anhydroglucitol (1,5-AG) levels have been suggested as a means of assessing glycemic excursions [11]. 1,5-AG is a polyol maintained within stable limits in subjects with healthy glucose levels. Its reabsorption in the kidney is inhibited by excessive excretion of urinary glucose; the higher the plasma glucose concentration, the lower the concentration of plasma 1,5-AG [12]. Urinary glucose only appears at plasma glucose concentrations over 160 mg/dL; therefore, 1,5-AG level seems of little use in detecting glucose fluctuations below this range. In addition, because both chronic and intermittent hyperglycemia are characterized by low concentrations of 1,5-AG, the correlation between glucose variability and 1,5-AG is poor when mean glucose levels remain high persistently. Use of the 1,5-AG concentration as a clinical marker is therefore limited to patients with postprandial hyperglycemia with HbA1c levels below 8% [1314]. Even though, 1,5-AG is not able to provide a direct measurement of glucose fluctuations, limiting the ability of this method to measure both the size and frequency of glycemic excursions.
Interday variability
The easiest way to measure interday variability of serum glucose is by calculating the SD of the fasting blood glucose concentration [15]. The absolute mean of daily differences (MODD) using hourly blood sampling was developed as a supplement to MAGE and mean blood glucose testing; this approach calculates the mean absolute value of the differences between glucose values on two consecutive days at the same time [16]. However, the timing of meals can greatly affect MODD scores, making a strict dietary regimen essential for accurate monitoring.
Long-term variability
The SD of the fasting blood glucose or HbA1c can be used to assess long-term variability in serum glucose levels, the latter of which having been found to be a significant prognostic factor for microvascular complications, as discussed below.
It has been suggested that glucose variability may have been responsible for differences in microvascular outcomes between intensively and conventionally treated T1DM patients with the same mean HbA1c in the Diabetes Control and Complications Trial (DCCT) [17]. Although this hypothesis has since been refuted by the study authors themselves [18], interest in the relationship between glucose variability and chronic complications of diabetes has persisted. This interest has yet to progress to the point of randomized clinical trials, making the connection between these two factors largely speculative.
Hyperglycemia is thought to induce oxidative stress, which has been shown to exacerbate diabetic complications through a variety of molecular mechanisms [19]. The proposed contribution of glucose variability is supported by reports that oxidative stress is greater for intermittent as opposed to sustained hyperglycemia [202122], though contradictory evidence has also been reported [132324].
Microvascular complications
In the case of T1DM, a large proportion of studies have been secondary analyses of either the DCCT or the follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study. In these studies, the SD of SMBG results revealed no relationship between glucose variability and the risk of development or progression of microvascular complications (retinopathy and/or nephropathy) [18252627]. Glucose variability did not contribute to the development of neuropathy, although neuropathy data were more limited than other clinical covariates [28]. However, according to a prospective observational study that followed 100 patients with T1DM for 11 years, the SD of SMBG was found to be significantly related only with peripheral neuropathy and a borderline predictor of incidence (hazard ratio, 1.73; P=0.07) [29]. Therefore, these data suggest that the nervous system may be particularly vulnerable to glycemic variability. However, these studies relied on SMBG data, which may miss fluctuations occurring between the measurements.
A similar study assessing glycemic variability in T1DM patients using both CGM and SMBG readings revealed a strong correlation between microvascular complications and higher glycemic variability by CGM, but not by SMBG [30]. However, reproducibility remains an issue, with a conflicting report demonstrating no significant association between retinopathy and measures of glucose variability using CGM data in either T1DM or type 2 diabetes mellitus (T2DM) [31]. More studies are therefore necessary to determine the relationship between intraday glycemic variability and microvascular complications. In the meantime, long-term fluctuations such as HbA1c variability and the CV/SD of fasting blood glucose have been implicated in the development of retinopathy or nephropathy in T1DM [32] and T2DM [3334] by retrospective analyses. However, even these associations remain controversial [35].
Macrovascular complications
In terms of the DCCT study, the SD was not a predictor of cardiovascular events in patients with T1DM [36]. As for T2DM, some evidence of long-term variability in fasting plasma glucose as a prognostic factor for cardiovascular mortality has been seen in elderly patients [37]. Recent 7-point glucose data from the HEART2D study comparing basal insulin and prandial insulin after acute myocardial infarction (Fig. 3) reported no association between the mean absolute glucose (MAG), an intraday assessment of glucose variability, and the endpoint of combined cardiovascular events [38]. Because neither SD nor MAGE was significantly different between the two treatment groups, this interpretation has been challenged in part due to the reliance on MAG, with no other methods used to assess variability [39]. In the meanwhile, in patients with acute myocardial infarction, MAGE from CGM data collected at the time of admission independently predicted major adverse cardiac events [4041]. A subsequent cross-sectional study also showed that short-term glucose variability, as determined by CGM, was associated with the severity of coronary artery disease [42]. When we look at studies of surrogate endpoints such as subclinical atherosclerosis, more supportive evidence for associations with glucose variability can be found both in T1DM and T2DM [43444546]. However, a substantial proportion of the T2DM studies included mixed populations of patients treated with diet alone, diet and oral antidiabetic medications, and insulin. As such, this may have been a confounding factor in many of the findings, requiring further subgroup analyses to more accurately assess risk factors in this population.
While the data remain very heterogeneous, some conclusions can be drawn from this literature review. First, in the absence of a true gold standard for determining glucose variability, MAGE and SD have become the go-to methods for variability testing. CGM systems appear to be preferable to SMBG for capturing variability because of the larger number of data points possible with this approach. Second, little supporting evidence linking short-term glucose variability and microvascular complications exists, with full confirmation requiring use of a CGM system, particularly in patients with T1DM. The bulk of the T1DM data were derived from a single study (DCCT), limiting the generalizability of some conclusions; further studies are necessary to determine whether these findings are consistent across different populations. Prospective analyses examining the effects of long-term variability on microvascular complications are also needed. As for macrovascular complications, although the HEART2D trial suggested that lowering glucose variability does not improve cardiovascular outcomes in T2DM patients after acute myocardial infarction, subsequent studies demonstrated that glycemic variability has a probability of accelerating coronary artery disease in high-risk patients with T2DM. Large-scale randomized controlled trials are necessary to establish such a risk.
Acknowledgements
This study was supported by a grant from the Innovative Research Institute for Cell Therapy (A062260) by the Ministry of Health and Welfare, Republic of Korea.

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

  • 1. Service FJ. Glucose variability. Diabetes 2013;62:1398–1404. ArticlePubMedPMC
  • 2. Facchinetti A, Sparacino G, Cobelli C. Modeling the error of continuous glucose monitoring sensor data: critical aspects discussed through simulation studies. J Diabetes Sci Technol 2010;4:4–14. ArticlePubMedPMC
  • 3. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008;36:3008–3013. ArticlePubMed
  • 4. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244–252. ArticlePubMed
  • 5. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010;31:171–182. ArticlePubMedPDF
  • 6. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644–655. ArticlePubMed
  • 7. Baghurst PA. Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. Diabetes Technol Ther 2011;13:296–302. ArticlePubMed
  • 8. Schlichtkrull J, Munck O, Jersild M. The M-valve, an index of blood-sugar control in diabetics. Acta Med Scand 1965;177:95–102. ArticlePubMed
  • 9. Moberg E, Kollind M, Lins PE, Adamson U. Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 1993;53:507–514. ArticlePubMed
  • 10. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005;7:253–263. ArticlePubMed
  • 11. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T. 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995;18:1156–1159. ArticlePubMed
  • 12. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003;5:355–363. ArticlePubMed
  • 13. Kim MJ, Jung HS, Hwang-Bo Y, Cho SW, Jang HC, Kim SY, Park KS. Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol 2013;50:505–510. ArticlePubMedPDF
  • 14. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006;29:1214–1219. ArticlePubMed
  • 15. Shima K, Tanaka R, Morishita S, Tarui S, Kumahara Y. Studies on the etiology of "brittle diabetes". Relationship between diabetic instability and insulinogenic reserve. Diabetes 1977;26:717–725. ArticlePubMed
  • 16. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972;8:342–348. ArticlePubMedPDF
  • 17. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707–1708. ArticlePubMed
  • 18. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial: revisited. Diabetes 2008;57:995–1001. ArticlePubMed
  • 19. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820. ArticlePubMedPDF
  • 20. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349–1354. ArticlePubMed
  • 21. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010;53:562–571. ArticlePubMedPDF
  • 22. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–1687. ArticlePubMed
  • 23. Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries JH. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol 2011;5:86–92. ArticlePubMedPMC
  • 24. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008;51:183–190. ArticlePubMedPDF
  • 25. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29:1486–1490. ArticlePubMed
  • 26. Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009;32:1901–1903. ArticlePubMedPMC
  • 27. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001;44:1215–1220. ArticlePubMedPDF
  • 28. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009;52:2229–2232. ArticlePubMedPMCPDF
  • 29. Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008;34(6 Pt 1):612–616. ArticlePubMed
  • 30. Soupal J, Skrha J Jr, Fajmon M, Horova E, Mraz M, Skrha J, Prazny M. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther 2014;16:198–203. ArticlePubMed
  • 31. Sartore G, Chilelli NC, Burlina S, Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol 2013;50:437–442. ArticlePubMedPDF
  • 32. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198–2202. ArticlePubMedPMC
  • 33. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications 2003;17:78–81. ArticlePubMed
  • 34. Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y. The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract 2011;91:e40–e42. ArticlePubMed
  • 35. Zoppini G, Verlato G, Targher G, Casati S, Gusson E, Biasi V, Perrone F, Bonora E, Muggeo M. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutr Metab Cardiovasc Dis 2009;19:334–339. ArticlePubMed
  • 36. Kilpatrick ES, Rigby AS, Atkin SL. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 2008;51:365–371. ArticlePubMedPDF
  • 37. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997;96:1750–1754. ArticlePubMed
  • 38. Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011;34:855–857. ArticlePubMedPMC
  • 39. Monnier L, Colette C. Glycemic variability: can we bridge the divide between controversies? Diabetes Care 2011;34:1058–1059. ArticlePubMedPMC
  • 40. Su G, Mi SH, Tao H, Li Z, Yang HX, Zheng H, Zhou Y, Tian L. Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care 2013;36:1026–1032. ArticlePubMedPMC
  • 41. Wang X, Zhao X, Dorje T, Yan H, Qian J, Ge J. Glycemic variability predicts cardiovascular complications in acute myocardial infarction patients with type 2 diabetes mellitus. Int J Cardiol 2014;172:498–500. ArticlePubMed
  • 42. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011;10:19ArticlePubMedPMC
  • 43. Esposito K, Giugliano D, Nappo F, Marfella R. Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214–219. ArticlePubMed
  • 44. Snell-Bergeon JK, Roman R, Rodbard D, Garg S, Maahs DM, Schauer IE, Bergman BC, Kinney GL, Rewers M. Glycaemic variability is associated with coronary artery calcium in men with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabet Med 2010;27:1436–1442. ArticlePubMedPMC
  • 45. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013;227:349–354. ArticlePubMed
  • 46. Mo Y, Zhou J, Li M, Wang Y, Bao Y, Ma X, Li D, Lu W, Hu C, Li M, Jia W. Glycemic variability is associated with subclinical atherosclerosis in Chinese type 2 diabetic patients. Cardiovasc Diabetol 2013;12:15ArticlePubMedPMC
  • 47. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381–386. ArticlePubMedPMC
Fig. 1

Twenty-four-hour glycemic curves of two patients with diabetes (red and blue lines). The two patients exhibit different patterns of glycemic variation; however, standard deviations calculated across all four points, before each meal and at bedtime (arrows), do not reflect this because the glucose measures are similar between the two patients at those points.

enm-30-167-g001.jpg
Fig. 2

Continuous glucose monitoring in a patient with type 1 diabetes mellitus. Qualifying excursions are shown as blue arrows (only the inflection components in this case). Each inflection incorporates several excursions smaller than 1 standard deviation (SD) within a given day (44 mg/dL for day 1 and 65 mg/dL for day 2). The averaged excursion (that is, mean amplitude of glycemic excursion [MAGE]) is (A) 85.0 mg/dL for day 1 and (B) 156.5 mg/dL for day 2. MAGE calculated from the entire 48-hour time course (SD, 56.5 mg/dL) was 131.5 mg/dL; this level was similar across each day of the study period (120.7 mg/dL). Similar MAGE values could also be calculated from the descending limbs.

enm-30-167-g002.jpg
Fig. 3

Glycemic measures in a randomized controlled trial comparing prandial and basal insulin in patients with cardiovascular disease (HEART2D study). Seven-point mean self-monitoring of blood glucose profiles at baseline (dotted line) and throughout the study (solid line) are indicative of the treatment strategy. Only the change in the mean absolute glucose level, an alleged measure of glucose variability, was significantly different between treatments, with no observable differences in standard deviation or mean amplitude of glycemic excursion. Therefore, accurate interpretation of the relationship between glycemic variability and the endpoint of combined cardiovascular events in this trial is prudent. Adapted from Raz et al. [47], with permission from American Diabetes Association. aP<0.05 between treatment.

enm-30-167-g003.jpg
Table 1

Formulas Used to Describe Glucose Variability

enm-30-167-i001.jpg
Variability measure Formula Explanation of symbols
SD xi-x¯2k-1enm-30-167-i002.jpg xi=individual observation
=mean of observations
k=number of observations
CV sx¯enm-30-167-i003.jpg s=standard deviation
=mean of observations
MAGE λn if λ>venm-30-167-i004.jpg λ=each blood glucose increase or decrease (nadir-peak or peak nadir)
n=number of observations
v=1 SD of mean glucose for 24-hour period
Adjusted M value MGR+MWwhere MGR=t=titklog10GRtIGV3n and MW=Gmax-Gmin20enm-30-167-i005.jpg MGR=M-value for glucose readings
Mw=correction factor for n<24
GRt=glucose reading at time t
IGV=ideal glucose value
ti=time in minutes after start of observations of the ith observation
Gmax=maximum glucose reading
Gmin=minimum glucose reading
J-index 0.001×(MBG+SD)2 for glucose measured in mg/dL
CONGA t=titk*D-D¯2k*-1enm-30-167-i006.jpg where Dt=GRt - GRt-m and D¯=t=titk*Dtk*enm-30-167-i007.jpg k*=number of observations where there is an observation n×60 minutes ago
m=n×60
Dt=difference between glucose reading at time t and t minus n hours ago
MODD D=t=titk*GRi-GRi-1440k*enm-30-167-i008.jpg

Units are in mmol/L or mg/dL depending on the unity of the glucose values measured. To convert glucose values from mg/dL to mmol/L multiply by 0.0555. Adapted from Siegelaar et al. [5], with permission from Endocrine Society.

SD, standard deviation; CV, coefficient of variation; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; CONGA, continuous overall net glycemic action; MODD, mean of daily difference.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • A randomized trial on the effect of transcutaneous electrical nerve stimulator on glycemic control in patients with type 2 diabetes
      Jin-Ying Lu, Horng-Yih Ou, Chung-Ze Wu, Chwen-Yi Yang, Ju-Ying Jiang, Chieh-Hsiang Lu, Yi-Der Jiang, Tien-Jyun Chang, Yi-Cheng Chang, Meng-Lun Hsieh, Wan-Chen Wu, Hung-Yuan Li, Ye-Fong Du, Ching-Han Lin, Hao-Chang Hung, Kai-Jen Tien, Nai-Cheng Yeh, Shang-
      Scientific Reports.2023;[Epub]     CrossRef
    • Association between initial in-hospital heart rate and glycemic control in patients with acute ischemic stroke and diabetes mellitus
      Ya-Wen Kuo, Jiann-Der Lee, Chuan-Pin Lee, Yen-Chu Huang, Meng Lee
      BMC Endocrine Disorders.2023;[Epub]     CrossRef
    • Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies
      Jeff Unger, Denise R. Franco
      Diabetes Technology & Therapeutics.2023; 25(S3): S-21.     CrossRef
    • Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality
      Ji Yoon Kim, Jee Hee Yoo, Jae Hyeon Kim
      Diabetes Technology & Therapeutics.2023; 25(12): 883.     CrossRef
    • Personalized diabetes monitoring platform leveraging IoMT and AI for non-invasive estimation
      Durga Padmavilochanan, Rahul Krishnan Pathinarupothi, K.A. Unnikrishna Menon, Harish Kumar, Ramesh Guntha, Maneesha V. Ramesh, P. Venkat Rangan
      Smart Health.2023; 30: 100428.     CrossRef
    • Acute effects of drinks containing blackcurrant and citrus (poly)phenols and dietary fibre on postprandial glycaemia, gut hormones, cognitive function and appetite in healthy adults: two randomised controlled trials
      Ana M. Pinto, Mark R. Hobden, Katherine D. Brown, Jonathan Farrimond, Darren Targett, Christopher P. Corpe, Peter R. Ellis, Yvanna Todorova, Klaudia Socha, Shatha Bahsoon, Claudia Haworth, Morgane Marcel, Xirui Nie, Wendy L. Hall
      Food & Function.2023; 14(22): 10163.     CrossRef
    • Metabolomics in diabetes mellitus: clinical insight
      Shereen M. Aleidi, Hiba Al Fahmawi, Afshan Masood, Anas Abdel Rahman
      Expert Review of Proteomics.2023; 20(12): 451.     CrossRef
    • Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study)
      Ji Cheol Bae, Soo Heon Kwak, Hyun Jin Kim, Sang-Yong Kim, You-Cheol Hwang, Sunghwan Suh, Bok Jin Hyun, Ji Eun Cha, Jong Chul Won, Jae Hyeon Kim
      Diabetes & Metabolism Journal.2022; 46(1): 81.     CrossRef
    • Glycemic Variability and Diabetes Mellitus
      Han Na Jang, Hye Seung Jung
      The Journal of Korean Diabetes.2022; 23(1): 12.     CrossRef
    • Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial
      Pavle Vrebalov Cindro, Mladen Krnić, Darko Modun, Jonatan Vuković, Tina Tičinović Kurir, Goran Kardum, Doris Rušić, Ana Šešelja Perišin, Josipa Bukić
      JMIR Formative Research.2022; 6(7): e35655.     CrossRef
    • Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability
      Ye Huang, Long Yue, Jiahuang Qiu, Ming Gao, Sijin Liu, Jingshang Wang
      Hormone and Metabolic Research.2022; 54(07): 419.     CrossRef
    • Therapeutic potential of paeoniflorin in atherosclerosis: A cellular action and mechanism-based perspective
      Wei Yu, Iqra Ilyas, Xuerui Hu, Suowen Xu, Hui Yu
      Frontiers in Immunology.2022;[Epub]     CrossRef
    • Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
      Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
      Diabetes & Metabolism Journal.2021; 45(3): 339.     CrossRef
    • Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy
      Junpeng Yang, Xueli Yang, Dongni Zhao, Xiaobing Wang, Wei Wei, Huijuan Yuan
      Journal of Diabetes Investigation.2021; 12(5): 828.     CrossRef
    • The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes
      Min Young Kim, Gyuri Kim, Ji Yun Park, Min Sun Choi, Ji Eun Jun, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
      Diabetes Technology & Therapeutics.2021; 23(6): 434.     CrossRef
    • Current concepts and clinical importance of glycemic variability
      Ramya Ravi, V Balasubramaniam, Gowthamarajan Kuppusamy, Sivasankaran Ponnusankar
      Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(2): 627.     CrossRef
    • Glycemic deviation index: a novel method of integrating glycemic numerical value and variability
      Yizhou Zou, Wanli Wang, Dongmei Zheng, Xu Hou
      BMC Endocrine Disorders.2021;[Epub]     CrossRef
    • Relationship between short and long-term glycemic variability and oxidative stress in type 1 diabetes mellitus under daily life insulin treatment
      Tatiana Valente, Fernando Valente, Maria Beatriz Bastos Lucchesi, Giovana Rita Punaro, Margaret Gori Mouro, Monica Andrade Lima Gabbay, Elisa Mieko Suemitsu Higa, Sergio Atala Dib
      Archives of Endocrinology and Metabolism.2021;[Epub]     CrossRef
    • Evidence of Early Diabetic Nephropathy in Pediatric Type 1 Diabetes
      Leena Mamilly, Lucy D. Mastrandrea, Claudia Mosquera Vasquez, Brett Klamer, Mahmoud Kallash, Ahmad Aldughiem
      Frontiers in Endocrinology.2021;[Epub]     CrossRef
    • Glucose Variability and Risk of Hepatocellular Carcinoma in Patients with Diabetes: A Nationwide Population-Based Study
      Jeong-Ju Yoo, Eun Ju Cho, Kyungdo Han, Soo Seong Heo, Bo-Yeon Kim, Dong Wook Shin, Su Jong Yu
      Cancer Epidemiology, Biomarkers & Prevention.2021; 30(5): 974.     CrossRef
    • Effect of glucose concentration and culture substrate on HUVECs viability in in vitro cultures: A literature review and own results
      Anna Ciechanowska, Ilona Gora, Stanislawa Sabalinska, Piotr Foltynski, Piotr Ladyzynski
      Biocybernetics and Biomedical Engineering.2021; 41(4): 1390.     CrossRef
    • Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study
      Kyoung Jin Kim, Jimi Choi, Jae Hyun Bae, Kyeong Jin Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim, Nam Hoon Kim
      Diabetes & Metabolism Journal.2021; 45(3): 368.     CrossRef
    • Immunosuppressive PLGA TGF-β1 Microparticles Induce Polyclonal and Antigen-Specific Regulatory T Cells for Local Immunomodulation of Allogeneic Islet Transplants
      Ying Li, Anthony W. Frei, Irayme M. Labrada, Yanan Rong, Jia-Pu Liang, Magdalena M. Samojlik, Chuqiao Sun, Steven Barash, Benjamin G. Keselowsky, Allison L. Bayer, Cherie L. Stabler
      Frontiers in Immunology.2021;[Epub]     CrossRef
    • Retrospective study of glycemic variability, BMI, and blood pressure in diabetes patients in the Digital Twin Precision Treatment Program
      Paramesh Shamanna, Mala Dharmalingam, Rakesh Sahay, Jahangir Mohammed, Maluk Mohamed, Terrence Poon, Nathan Kleinman, Mohamed Thajudeen
      Scientific Reports.2021;[Epub]     CrossRef
    • Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice
      Phyu Phyu Khin, Yeonhee Hong, MyeongHoon Yeon, Dae Ho Lee, Jong Han Lee, Hee-Sook Jun
      Aging.2021; 13(18): 21962.     CrossRef
    • Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus
      Tatiana Valente, Alberto K. Arbex
      Current Diabetes Reviews.2021;[Epub]     CrossRef
    • The impact of structured self-monitoring of blood glucose on glycaemic variability in non-insulin treated type 2 diabetes: The SMBG study, a 12-month randomised controlled trial
      David M. Williams, Sharon N. Parsons, Gareth J. Dunseath, Jeffrey W. Stephens, Stephen D. Luzio, David R. Owens
      Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(2): 101.     CrossRef
    • Model‐based data analysis of individual human postprandial plasma bile acid responses indicates a major role for the gallbladder and intestine
      Emma C. E. Meessen, Fianne L. P. Sips, Hannah M. Eggink, Martijn Koehorst, Johannes A. Romijn, Albert K. Groen, Natal A. W. Riel, Maarten R. Soeters
      Physiological Reports.2020;[Epub]     CrossRef
    • How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes?
      R. Livingstone, J. G. Boyle, J. R. Petrie
      Diabetic Medicine.2020; 37(4): 513.     CrossRef
    • Simple Linear Support Vector Machine Classifier Can Distinguish Impaired Glucose Tolerance Versus Type 2 Diabetes Using a Reduced Set of CGM-Based Glycemic Variability Indices
      Enrico Longato, Giada Acciaroli, Andrea Facchinetti, Alberto Maran, Giovanni Sparacino
      Journal of Diabetes Science and Technology.2020; 14(2): 297.     CrossRef
    • Vascular Complication in Adolescents With Diabetes Mellitus
      Lara E. Graves, Kim C. Donaghue
      Frontiers in Endocrinology.2020;[Epub]     CrossRef
    • The Association Between Glycemic Variability and Macronutrients in Young Children with T1D
      Alexandra D Monzon, Laura B Smith, Scott W Powers, Lawrence M Dolan, Susana R Patton
      Journal of Pediatric Psychology.2020; 45(7): 749.     CrossRef
    • Effect of sancai powder on glacemic variability of type 1 diabetes in China
      Weiwei Yu, Dongqi Zhou, Li Zhang, Chen Rumeng, Peishuai Zhang, Lisha Sun, Ziping Gao
      Medicine.2020; 99(34): e20772.     CrossRef
    • Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release
      Anna L. Krämer, Angelina Riederer, Federico Fracassi, Felicitas S. Boretti, Nadja S. Sieber‐Ruckstuhl, Thomas A. Lutz, Barbara Contiero, Eric Zini, Claudia E. Reusch
      Journal of Veterinary Internal Medicine.2020; 34(6): 2287.     CrossRef
    • The Association Between Glycemic Variability and Myocardial Infarction: A Review and Meta-Analysis of Prospective Studies and Randomized Trials
      Zinab Alatawi, Hyder Mirghani
      Cureus.2020;[Epub]     CrossRef
    • Epigenetic regulation by polyphenols in diabetes and related complications
      Hammad Ullah, Anna De Filippis, Cristina Santarcangelo, Maria Daglia
      Mediterranean Journal of Nutrition and Metabolism.2020; 13(4): 289.     CrossRef
    • A Protective Role of Paeoniflorin in Fluctuant Hyperglycemia-Induced Vascular Endothelial Injuries through Antioxidative and Anti-Inflammatory Effects and Reduction of PKCβ1
      Jing-Shang Wang, Ye Huang, Shuping Zhang, Hui-Jun Yin, Lei Zhang, Yan-Hong Zhang, Ye-Wen Song, Dan-Dan Li
      Oxidative Medicine and Cellular Longevity.2019; 2019: 1.     CrossRef
    • The mechanisms of glycemic variability accelerate diabetic central neuropathy and diabetic peripheral neuropathy in diabetic rats
      Junpeng Yang, Zhigang Zhao, Huijuan Yuan, Xiangxiang Ma, Yakun Li, Huimeng Wang, Xiaojun Ma, Guijun Qin
      Biochemical and Biophysical Research Communications.2019; 510(1): 35.     CrossRef
    • Glucose Variability and Coronary Artery Disease
      Jinggang Xia, Chunlin Yin
      Heart, Lung and Circulation.2019; 28(4): 553.     CrossRef
    • Phase 1 Study of the Pharmacology of BTI320 Before High‐Glycemic Meals
      David R. Luke, Karen Ka Yan Lee, Carl W. Rausch, Camille Cheng
      Clinical Pharmacology in Drug Development.2019; 8(3): 395.     CrossRef
    • Information Technology for Supporting Self-Control in the Formation of a Rational Lifestyle for Diabetics Patients
      S. KIFORENKO, T. HONTAR, V. ORLENKO, K. IVASKIVA, T. OBELETS
      Kibernetika i vyčislitelʹnaâ tehnika.2019; 2019(3(197)): 80.     CrossRef
    • Impact of Carbohydrate on Glucose Variability in Patients with Type 1 Diabetes Assessed Through Professional Continuous Glucose Monitoring: A Retrospective Study
      Yi-Hsuan Lin, Yu-Yao Huang, Hsin-Yun Chen, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Chia-Hung Lin
      Diabetes Therapy.2019; 10(6): 2289.     CrossRef
    • Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes Subjects
      Sabina Paglialunga, Bruce H. Morimoto, Amparo de la Peña, Caroline Fortier
      Clinical Pharmacology in Drug Development.2018; 7(7): 676.     CrossRef
    • Higher Total Insulin Dose Has Positive Effect on Corneal Nerve Fibers in DM1 Patients
      Gabriela Mahelková, Marie Ceská Burdová, Šárka Malá, Lucie Hoskovcová, Dagmar Dotrelová, Katerina Štechová
      Investigative Opthalmology & Visual Science.2018; 59(10): 3800.     CrossRef
    • Relationship between Thyroid Function and Kidney Function in Patients with Type 2 Diabetes
      Ying Zhang, Yang Wang, Xiao Jun Tao, Qian Li, Feng Fei Li, Kok Onn Lee, Dong Mei Li, Jian Hua Ma
      International Journal of Endocrinology.2018; 2018: 1.     CrossRef
    • The correlation between glucose fluctuation from self-monitored blood glucose and the major adverse cardiac events in diabetic patients with acute coronary syndrome during a 6-month follow-up by WeChat application
      Jinggang Xia, Shaodong Hu, Ji Xu, Hengjian Hao, Chunlin Yin, Dong Xu
      Clinical Chemistry and Laboratory Medicine (CCLM).2018; 56(12): 2119.     CrossRef
    • Glycemic Variability Percentage: A Novel Method for Assessing Glycemic Variability from Continuous Glucose Monitor Data
      Thomas A. Peyser, Andrew K. Balo, Bruce A. Buckingham, Irl B. Hirsch, Arturo Garcia
      Diabetes Technology & Therapeutics.2018; 20(1): 6.     CrossRef
    • Efficacy and safety of Panax ginseng berry extract on glycemic control: A 12-wk randomized, double-blind, and placebo-controlled clinical trial
      Han Seok Choi, Sunmi Kim, Min Jung Kim, Myung-Sunny Kim, Juewon Kim, Chan-Woong Park, Daebang Seo, Song Seok Shin, Sang Woo Oh
      Journal of Ginseng Research.2018; 42(1): 90.     CrossRef
    • Resistance to Data Loss of Glycemic Variability Measurements in Long-Term Continuous Glucose Monitoring
      Przemysław Kucharski, Konrad Pagacz, Agnieszka Szadkowska, Wojciech Młynarski, Andrzej Romanowski, Wojciech Fendler
      Diabetes Technology & Therapeutics.2018; 20(12): 833.     CrossRef
    • Investigation of glucose fluctuations by approaches of multi-scale analysis
      Yunyun Lai, Zhengbo Zhang, Peiyao Li, Xiaoli Liu, YiXin Liu, Yi Xin, Weijun Gu
      Medical & Biological Engineering & Computing.2018; 56(3): 505.     CrossRef
    • Shared Responsibility for Type 1 Diabetes Care Is Associated With Glycemic Variability and Risk of Glycemic Excursions in Youth
      Arwen M Marker, Amy E Noser, Mark A Clements, Susana R Patton
      Journal of Pediatric Psychology.2018; 43(1): 61.     CrossRef
    • Self Blood Glucose Monitoring Underestimates Hyperglycemia And Hypoglycemia As Compared To Continuous Glucose Monitoring In Type 1 And Type 2 Diabetes
      Devna Mangrola, Christine Cox, Arianne S. Furman, Sridevi Krishnan, Sidika E. Karakas
      Endocrine Practice.2018; 24(1): 47.     CrossRef
    • Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients
      Marsida Teliti, Giulia Cogni, Lucia Sacchi, Arianna Dagliati, Simone Marini, Valentina Tibollo, Pasquale De Cata, Riccardo Bellazzi, Luca Chiovato
      Diabetes and Vascular Disease Research.2018; 15(5): 424.     CrossRef
    • Glucotypes reveal new patterns of glucose dysregulation
      Heather Hall, Dalia Perelman, Alessandra Breschi, Patricia Limcaoco, Ryan Kellogg, Tracey McLaughlin, Michael Snyder, Jason Locasale
      PLOS Biology.2018; 16(7): e2005143.     CrossRef
    • Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
      Satish K. Garg, Stuart A. Weinzimer, William V. Tamborlane, Bruce A. Buckingham, Bruce W. Bode, Timothy S. Bailey, Ronald L. Brazg, Jacob Ilany, Robert H. Slover, Stacey M. Anderson, Richard M. Bergenstal, Benyamin Grosman, Anirban Roy, Toni L. Cordero, J
      Diabetes Technology & Therapeutics.2017; 19(3): 155.     CrossRef
    • Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride
      Kyeong Seon Park, SooHeon Kwak, Young Min Cho, Kyong Soo Park, Hak C Jang, Seong Yeon Kim, Hye Seung Jung
      Journal of Diabetes Investigation.2017; 8(2): 218.     CrossRef
    • Role of the PKCβII/JNK signaling pathway in acute glucose fluctuation-induced apoptosis of rat vascular endothelial cells
      Na Wu, Haitao Shen, Yanjun Wang, Bing He, Yongyan Zhang, Yu Bai, Runyu Du, Qiang Du, Ping Han
      Acta Diabetologica.2017; 54(8): 727.     CrossRef
    • Association between glycemic variability and major adverse cardiovascular and cerebrovascular events (MACCE) in patients with acute coronary syndrome during 30-day follow-up
      Jinggang Xia, Ji Xu, Boyu Li, Zhi Liu, Hengjian Hao, Chunlin Yin, Dong Xu
      Clinica Chimica Acta.2017; 466: 162.     CrossRef
    • How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?
      Ramzi A. Ajjan
      Diabetes Technology & Therapeutics.2017; 19(S2): S-27.     CrossRef
    • The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus
      Gyuri Kim, Sewon Oh, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee
      Expert Opinion on Pharmacotherapy.2017; 18(12): 1179.     CrossRef
    • Association Between Coronary Artery Calcification and the Hemoglobin Glycation Index: The Kangbuk Samsung Health Study
      Eun-Jung Rhee, Jung-Hwan Cho, Hyemi Kwon, Se Eun Park, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
      The Journal of Clinical Endocrinology & Metabolism.2017; 102(12): 4634.     CrossRef
    • Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis
      Shuang Liang, Hang Yin, Chunxiang Wei, Linjun Xie, Hua He, Xiaoquan Liu
      Journal of Diabetes & Metabolic Disorders.2017;[Epub]     CrossRef
    • Could angiotensin-(1–7) be connected with improvement of microvascular function in diabetic patients? Angiotensin-(1–7) iontophoresis may provide the answer
      Aleksandar Kibel
      Medical Hypotheses.2016; 93: 16.     CrossRef
    • Efficacy and Safety of PDM011011 Capsules as Compared to Metformin in Subjects with Type-2 Diabetes Mellitus: An Open-Label, Randomized, Active-Controlled, Multicentric, Phase III Study
      Ashish C. Suthar, Vikas G. Pai, Yogesh Kadam, Aniruddha Tongaonkar, Shailaja Kale, Atul B. Deshpande, Sharat Kolke, Snehal Tanna, Shrikant V. Deshpande, Purvi Chawla, Debjit Biswas, Somesh Sharma
      Journal of Diabetes Mellitus.2016; 06(01): 38.     CrossRef
    • 1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy
      Min Kyeong Kim, Hye Seung Jung, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Seong Yeon Kim
      Endocrinology and Metabolism.2016; 31(2): 284.     CrossRef
    • The impact of glycemic variability on diabetic peripheral neuropathy
      Heung Yong Jin, Kyung Ae Lee, Tae Sun Park
      Endocrine.2016; 53(3): 643.     CrossRef
    • Serum bilirubin levels are positively associated with glycemic variability in women with type 2 diabetes
      Lee Kyung Kim, Eun Roh, Min Joo Kim, Min Kyeong Kim, Kyeong Seon Park, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Hye Seung Jung
      Journal of Diabetes Investigation.2016; 7(6): 874.     CrossRef
    • Wider Perioperative Glycemic Fluctuations Increase Risk of Postoperative Acute Kidney Injury
      Ming Ann Sim, Weiling Liu, Roderica R.G. Ng, Lian Kah Ti, Sophia T.H. Chew
      Medicine.2015; 94(44): e1953.     CrossRef

    • PubReader PubReader
    • Cite
      CITE
      export Copy
      Close
    • XML DownloadXML Download
    Figure

    Endocrinol Metab : Endocrinology and Metabolism